Research Progress on Strategies that can Enhance the Therapeutic Benefits of Mesenchymal Stromal Cells in Respiratory Diseases With a Specific Focus on Acute Respiratory Distress Syndrome and Other Inflammatory Lung Diseases
(2021) In Frontiers in Pharmacology 12.- Abstract
Recent advances in cell based therapies for lung diseases and critical illnesses offer significant promise. Despite encouraging preclinical results, the translation of efficacy to the clinical settings have not been successful. One of the possible reasons for this is the lack of understanding of the complex interaction between mesenchymal stromal cells (MSCs) and the host environment. Other challenges for MSC cell therapies include cell sources, dosing, disease target, donor variability, and cell product manufacturing. Here we provide an overview on advances and current issues with a focus on MSC-based cell therapies for inflammatory acute respiratory distress syndrome varieties and other inflammatory lung diseases.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/7f739f53-94c4-49c4-ad90-abb8878b1deb
- author
- Rolandsson Enes, Sara LU ; Krasnodembskaya, Anna D. ; English, Karen ; Dos Santos, Claudia C. and Weiss, Daniel J.
- organization
- publishing date
- 2021-04-19
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- cell therapy, lung diseases, mesenchymal stromal cells (MSCs), mscs, respiratory diseases and disorders
- in
- Frontiers in Pharmacology
- volume
- 12
- article number
- 647652
- publisher
- Frontiers Media S. A.
- external identifiers
-
- scopus:85105171612
- pmid:33953680
- ISSN
- 1663-9812
- DOI
- 10.3389/fphar.2021.647652
- language
- English
- LU publication?
- yes
- id
- 7f739f53-94c4-49c4-ad90-abb8878b1deb
- date added to LUP
- 2021-05-21 15:59:29
- date last changed
- 2024-08-10 16:15:38
@article{7f739f53-94c4-49c4-ad90-abb8878b1deb, abstract = {{<p>Recent advances in cell based therapies for lung diseases and critical illnesses offer significant promise. Despite encouraging preclinical results, the translation of efficacy to the clinical settings have not been successful. One of the possible reasons for this is the lack of understanding of the complex interaction between mesenchymal stromal cells (MSCs) and the host environment. Other challenges for MSC cell therapies include cell sources, dosing, disease target, donor variability, and cell product manufacturing. Here we provide an overview on advances and current issues with a focus on MSC-based cell therapies for inflammatory acute respiratory distress syndrome varieties and other inflammatory lung diseases.</p>}}, author = {{Rolandsson Enes, Sara and Krasnodembskaya, Anna D. and English, Karen and Dos Santos, Claudia C. and Weiss, Daniel J.}}, issn = {{1663-9812}}, keywords = {{cell therapy; lung diseases; mesenchymal stromal cells (MSCs); mscs; respiratory diseases and disorders}}, language = {{eng}}, month = {{04}}, publisher = {{Frontiers Media S. A.}}, series = {{Frontiers in Pharmacology}}, title = {{Research Progress on Strategies that can Enhance the Therapeutic Benefits of Mesenchymal Stromal Cells in Respiratory Diseases With a Specific Focus on Acute Respiratory Distress Syndrome and Other Inflammatory Lung Diseases}}, url = {{http://dx.doi.org/10.3389/fphar.2021.647652}}, doi = {{10.3389/fphar.2021.647652}}, volume = {{12}}, year = {{2021}}, }